During the past decade, Florida Cancer Specialist, North Region conducted 33 clinical trials. In the 10-year time frame, 33 clinical trials started and 13 clinical trials were completed, i.e. on average, 39.4% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 9 clinical trials were completed. i.e. 69.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Florida Cancer Specialist, North Region" #1 sponsor was "Hoffmann-La Roche" with 16 trials, followed by "Seagen Inc." with 8 trials sponsored, "Genentech, Inc." with 3 trials sponsored, "Incyte Corporation" with 2 trials sponsored and "BeiGene" with 2 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Florida Cancer Specialist, North Region" #1 collaborator was "Merck Sharp & Dohme LLC" with 3 trials as a collaborator, "Academic and Community Cancer Research United" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Flatiron Health, Inc.; Foundation Medicine, Inc." with 1 trials as a collaborator and "National Cancer Institute (NCI)" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Florida Cancer Specialist, North Region" are "Non-Small Cell Lung Cancer" (3 trials), "HER2 Positive Breast Cancer" (2 trials), "Lung Cancer" (2 trials), "Non-small Cell Lung Cancer (NSCLC)" (2 trials) and "Renal Cell Carcinoma" (2 trials). Many other conditions were trialed in "Florida Cancer Specialist, North Region" in a lesser frequency.

Most popular intervention types in "Florida Cancer Specialist, North Region" are "Drug" (32 trials) and "Other" (4 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (12 trials), "Placebo" (6 trials), "Tiragolumab" (6 trials), "Pembrolizumab" (5 trials) and "Bevacizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Florida Cancer Specialist, North Region" are 33 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Florida Cancer Specialist, North Region". undefined are not yet recruiting, 8 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Florida Cancer Specialist, North Region, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Florida Cancer Specialist, North Region, 1 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".